News
Shares of Hims & Hers Health skyrocketed to 40% in the premarket following the telehealth company’s partnership announcement ...
Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Hims & Hers ( HIMS) stock popped more than 20% in trading early Tuesday after Novo Nordisk ( NVO) announced a partnership with it and other telehealth platforms to offer patients access to the ...
Novo Nordisk collaborates with telehealth companies to expand sales and access to its weight-loss drug Wegovy, amidst efforts ...
Telehealth company Hims & Hers (HIMS) announced Tuesday that it will begin selling Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy.
Hims and Hers Health Inc. soared in pre-market trading after Novo Nordisk A/S said it would sell its popular weight-loss drug ...
Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...
In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this week ...
Hims & Hers stock surges after Novo Nordisk announces Wegovy will be offered through telehealth platforms as shortages ease ...
We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results